News

The additional data and analyses constitute a major amendment to the BLA, resulting in an extension of the Prescription Drug User Fee Act (PDUFA) goal date by three

Maud Brandely, Chief Medical Officer of Transgene, said: “We are pleased to be continuing the development of our internally discovered and developed immunotherapy TG1050. The Phase 1/1b trial

Upon completion and once fully evaluated, which is expected to take approximately 9-12 months, this clinical trial material will also be available to recommence dosing of patients in the Company’s

The Reprove trial evaluated the efficacy of Zavicefta compared to meropenem in the treatment of adult patients with hospital-acquired pneumonia, including ventilator-associated pneumonia. The antibiotic met the primary

Apex’s lead drug candidate APX3330 is a small molecule that targets the redox effector factor-1 (Ref-1) protein which regulates the activation of oncogenic transcription factors. The first part

In conjunction with the financing, Andrew Levin, M.D., Ph.D., managing director of RA Capital Management, will join Synthorx’s board of directors. Leveraging a synthetic biology breakthrough, Synthorx has

Under the terms of the agreement, Sapience will gain exclusive rights to the development and commercialization of intellectual property developed at Columbia University by Drs. Lloyd Greene and

West-Ward's Capecitabine Tablets are indicated for adjuvant treatment in patients with Dukes' C colon cancer, as monotherapy in metastatic colorectal cancer, and in combination with docetaxel or as

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, annual technology access payments, and is eligible to receive payments based on achievement of certain